MK-8245

/static/temp/default.svg

Search structure


Synonyms	Mk-8245
Status
Molecule Category	UNKNOWN
UNII	537E7QE8LX
EPA CompTox	DTXSID80145625


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	UJEAABFSXKCSGI-UHFFFAOYSA-N
Smiles	O=C(O)Cn1nnc(-c2cc(N3CCC(Oc4cc(F)ccc4Br)CC3)no2)n1
InChI	InChI=1S/C17H16BrFN6O4/c18-12-2-1-10(19)7-13(12)28-11-3-5-24(6-4-11)15-8-14(29-22-15)17-20-23-25(21-17)9-16(26)27/h1-2,7-8,11H,3-6,9H2,(H,26,27)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C17H16BrFN6O4
Molecular Weight	467.26
AlogP	2.36
Hydrogen Bond Acceptor	9.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	6.0
Polar Surface Area	119.4
Molecular species	ACID
Aromatic Rings	3.0
Heavy Atoms	29.0

Assay Description	Organism	Bioactivity	Reference
Antidiabetic activity in C57BL/6 mouse LPD model assessed as reduction in liver SCD activity at 4.9 uM liver concentration dosed at 2 mg/kg, po measured 3 hrs post dosing	Mus musculus	89.0 %
Antidiabetic activity in C57BL/6 mouse LPD model assessed as reduction in liver SCD activity at 1.6 uM liver concentration dosed at 0.4 mg/kg, po measured 3 hrs post dosing	Mus musculus	49.0 %
Inhibition of mouse SCD-1	Mus musculus	3.0 nM
Inhibition of SCD1 in rat hepatocytes expressing OATP	Rattus norvegicus	68.0 nM
Inhibition of SCD1 in mouse liver assessed as reduction in conversion of [14C]stearic acid to [14C]oleic acid at 2 mg/kg, po measured after 3 hrs	Mus musculus	89.0 %
Inhibition of SCD1 in mouse liver assessed as reduction in conversion of [14C]stearic acid to [14C]oleic acid after at 0.4 mg/kg, po after 3 hrs	Mus musculus	49.0 %
Inhibition of SCD-1 activity in Sprague-Dawley rat microsome assessed as reduction in [I-14C] stearoyl CoA desaturation by scintillation counting	Rattus norvegicus	3.0 nM
Inhibition of SCD-1 activity in Sprague-Dawley rat Hepatocytes expressing organic anion transporting polypeptides assessed as reduction in [I-14C] stearoyl CoA desaturation by scintillation counting	Rattus norvegicus	68.0 nM
Inhibition of human SCD-1	Homo sapiens	1.0 nM
Inhibition of rat SCD-1	Rattus norvegicus	3.0 nM
Inhibition of mouse SCD-1	Mus musculus	3.0 nM
Antidiabetic activity in diet-induced obese C57BL6 mouse assessed as reduction in glucose AUC at 3 to 7 mg/kg, po administered 1 hr before oral glucose administration measured 2 hrs thereafter	Mus musculus	36.0 %
Antidiabetic activity in diet-induced obese C57BL6 mouse assessed as reduction in glucose AUC at 7 to 10 mg/kg, po administered 1 hr before oral glucose administration measured 2 hrs thereafter	Mus musculus	60.0 %
Antidiabetic activity in diet-induced obese C57BL6 mouse assessed as reduction in glucose AUC at 7 to 30 mg/kg, po administered 1 hr before oral glucose administration measured 2 hrs thereafter	Mus musculus	89.0 %
Inhibition of SCD activity in liver of diet-induced obese C57BL6 mouse assessed as reduction in desaturation induces at 20 mg/kg, po BID administered for 4 weeks	Mus musculus	63.0 %
Inhibition of SCD-1 activity in human Hepatocytes expressing organic anion transporting polypeptides assessed as reduction in [I-14C] stearoyl CoA desaturation after 1 hr by scintillation counting	Homo sapiens	5.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	-6.52 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	8.07 %		SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	4.29 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	1.84 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	1.96 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	1.84 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	1.96 %

Cross References

Resources	Reference
ChEMBL	CHEMBL1938870
DrugBank	DB13024
FDA SRS	537E7QE8LX
PubChem	24988881
SureChEMBL	SCHEMBL472978
ZINC	ZINC000043195878

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).